Working… Menu
Trial record 5 of 9 for:    progeria

Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome or Progeroid Laminopathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03895528
Expanded Access Status : Available
First Posted : March 29, 2019
Last Update Posted : February 16, 2021
Information provided by (Responsible Party):
Eiger BioPharmaceuticals

Tracking Information
First Submitted Date March 27, 2019
First Posted Date March 29, 2019
Last Update Posted Date February 16, 2021
Descriptive Information
Brief Title Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome or Progeroid Laminopathy
Brief Summary This treatment IND protocol will allow patients with HGPS and progeroid laminopathies access to lonafarnib, the only compound shown to have an effect on the HGPS disease process resulting in improved outcomes (Gordon et al, 2018). There are no approved treatments for HGPS and progeroid laminopathies.
Detailed Description Not Provided
Study Type Expanded Access
Expanded Access Type Treatment IND/Protocol
Intervention Drug: Lonafarnib
Farnesyl transferase inhibitor
Other Name: FTI
Publications * Gordon LB, Shappell H, Massaro J, D'Agostino RB Sr, Brazier J, Campbell SE, Kleinman ME, Kieran MW. Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome. JAMA. 2018 Apr 24;319(16):1687-1695. doi: 10.1001/jama.2018.3264.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Expanded Access Status Available
Contact: Senior Director, Clinical Affairs (650) 279-9845
Listed Location Countries Not Provided
Removed Location Countries  
Administrative Information
NCT Number NCT03895528
Responsible Party Eiger BioPharmaceuticals
Study Sponsor Eiger BioPharmaceuticals
Collaborators Not Provided
Investigators Not Provided
PRS Account Eiger BioPharmaceuticals
Verification Date February 2021